

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

LYNX THERAPEUTICS INC
Form SC 13G/A
February 14, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)

Lynx Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

000551812308

(CUSIP Number)

December 31, 2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

CUSIP NO. 000551812308

13G

1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Friedman, Billings, Ramsey Group, Inc.
54-1837743

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [] (b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
Virginia

5 SOLE VOTING POWER
1,807,150**

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER
0

7 SOLE DISPOSITIVE POWER
1,807,150**

8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,807,150**

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES *

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.93%

12 TYPE OF REPORTING PERSON*

HC

*SEE INSTRUCTION BEFORE FILLING OUT!

**SEE ITEM NO. 4

CUSIP NO. 000551812308

13G/A

1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Eric F. Billings

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [] (b) [X]

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5 SOLE VOTING POWER
0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6 SHARED VOTING POWER
1,807,150**

7 SOLE DISPOSITIVE POWER
0

8 SHARED DISPOSITIVE POWER
1,807,150**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,807,150**

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES *

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.93%

12 TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTION BEFORE FILLING OUT!

**SEE ITEM NO. 4

CUSIP NO. 000551812308

13G/A

1 NAME OF REPORTING PERSON

S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Emanuel J. Friedman

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [] (b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

	5	SOLE VOTING POWER	0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	1,807,150**
	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	1,807,150**
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,807,150**		
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES *		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	5.93%		
12	TYPE OF REPORTING PERSON*		
	IN		

*SEE INSTRUCTION BEFORE FILLING OUT!
**SEE ITEM NO. 4

Item 1. (a). Name of Issuer: Lynx Therapeutics, Inc.

(b). Address of Issuer's Principal Executive Offices:
25861 Industrial Blvd.
Hayward, CA 94545

Item 2. (a). Name of Person Filing:
Friedman, Billings, Ramsey Group, Inc.

(b). Address of Principal Business Office or, if none, Residence:
1001 19th Street North
Arlington, VA 22209-1710

(c). Citizenship: Virginia

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

(d). Title of Class of Securities: Common Stock

(e). CUSIP Number: 358433100

- Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 - (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 - (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c.);
 - (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C.80a-8);
 - (e) An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);
 - (f) An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F);
 - (g) A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G);
 - (h) A savings associations as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 - (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 - (j) Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a). Amount beneficially owned: 1,807,150**
- (b). Percent of class: 5.93%
- (c). Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 1,807,150**.
 - (ii) Shared power to vote or to direct the vote 0.
 - (iii) Sole power to dispose or to direct the disposition of 1,807,150**.
 - (iv) Shared power to dispose or to direct the disposition of 0.

**The 1,807,150 shares reported includes presently exercisable warrants to purchase 360,000 shares.

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

- Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable.
- Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
- Item 7. Identification and Classification of Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company:
Friedman, Billings, Ramsey Investment Management, Inc. 3(e)
Friedman, Billings, Ramsey & Co., Inc. 3(a)
- Item 8. Identification and Classification of Members of the Group:
Not Applicable.
- Item 9. Notice of Dissolution of Group:
Not Applicable.
- Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaims the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FRIEDMAN, BILLINGS, RAMSEY GROUP, INC.

Dated: February 14, 2003

By: /s/ EMANUEL J. FRIEDMAN

Name: Emanuel J. Friedman
Title: Chairman

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

Dated: February 14, 2003

/s/ ERIC F. BILLINGS

Eric F. Billings

Dated: February 14, 2003

/s/ EMANUEL J. FRIEDMAN

Emanuel J. Friedman